What changed in Bio-Rad Laboratories, Inc.'s latest annual report
In the year ended 31 Dec 2025, Bio-Rad Laboratories, Inc.'s revenue rose 0.7% to USD 2.58bn, from USD 2.57bn; shareholders' equity rose 13.5% to USD 7.45bn, from USD 6.57bn; total assets rose 12.9% to USD 10.58bn, from USD 9.36bn.
Year ended 31 Dec 2025. Source: 10-K filed 13 Feb 2026, read it on SEC EDGAR.
USD 2.57bn to USD 2.58bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 2.57bn | 2.58bn | Up 0.7% |
| Net income | -1.84bn | 759.90m | Not comparable |
| Total assets | 9.36bn | 10.58bn | Up 12.9% |
| Total liabilities | 2.79bn | 3.12bn | Up 11.7% |
| Long-term debt | 1.20bn | 1.20bn | Up 0.1% |
| Cash and cash equivalents | 488.10m | 529.80m | Up 8.5% |
| Shareholders' equity | 6.57bn | 7.45bn | Up 13.5% |
Questions people ask
Did Bio-Rad Laboratories, Inc.'s revenue grow last year?
Revenue grew 0.7%, from USD 2.57bn to USD 2.58bn in the year ended 31 Dec 2025.
Is Bio-Rad Laboratories, Inc. profitable?
Yes. Net income was USD 759.90m in the year ended 31 Dec 2025. The year before: a net loss of USD 1.84bn.
How much cash and debt does Bio-Rad Laboratories, Inc. have?
At its latest year end (31 Dec 2025), Bio-Rad Laboratories, Inc. reported cash and cash equivalents of USD 529.80m and long-term debt of USD 1.20bn.
Where do these numbers come from?
From Bio-Rad Laboratories, Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Bio-Rad Laboratories, Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Laboratory Analytical Instruments companies
- Agilent Technologies, Inc.Cash and cash equivalents up 34.6%
- Waters CorporationCash and cash equivalents up 80.7%
- Illumina, Inc.Shareholders' equity up 14.7%
- Mettler-Toledo International Inc.Total assets up 14.6%
- Revvity, IncCash and cash equivalents down 20.9%
- Avantor, Inc.Cash and cash equivalents up 39.5%
- 10x Genomics, Inc.Total liabilities up 17.5%